What Have We Learned from Perfusion MRI in Multiple Sclerosis?

References

1. 1.↵
   2. Grigoriadis N,
   3. van Pesch V,
   4. Paradig MS

   ; Paradig MS Group. A basic overview of multiple sclerosis immunopathology. Eur J Neurol 2015;22(suppl 2):3–13 doi:10.1111/ene.12798 pmid:26374508

   CrossRefPubMed
2. 2.↵
   2. Sati P,
   3. Oh J,
   4. Constable RT, et al

   . The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 2016;12:714–22 doi:10.1038/nrneurol.2016.166 pmid:27834394

   CrossRefPubMed
3. 3.↵
   2. Law M,
   3. Saindaine AM,
   4. Ge Y, et al

   . Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004;231:645–52 doi:10.1148/radiol.2313030996 pmid:15163806

   CrossRefPubMedWeb of Science
4. 4.↵
   2. D'haeseleer M,
   3. Hostenbach S,
   4. Peeters I, et al

   . Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis? J Cereb Blood Flow Metab 2015;35:1406–10 doi:10.1038/jcbfm.2015.131 pmid:26104292

   CrossRefPubMed
5. 5.↵
   2. Sun X,
   3. Tanaka M,
   4. Kondo S, et al

   . Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med 1998;12:89–94 doi:10.1007/BF03164835 pmid:9637279

   CrossRefPubMed
6. 6.↵
   2. Lycke J,
   3. Wikkelsö C,
   4. Bergh AC, et al

   . Regional cerebral blood flow in multiple sclerosis measured by single photon emission tomography with technetium-99m hexamethylpropyleneamine oxime. Eur Neurol 1993;33:163–67 pmid:8467826

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Brooks DJ,
   3. Leenders KL,
   4. Head G, et al

   . Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosurg Psychiatry 1984;47:1182–91 doi:10.1136/jnnp.47.11.1182 pmid:6334132

   Abstract/FREE Full Text
8. 8.↵
   2. Inglese M,
   3. Adhya S,
   4. Johnson G, et al

   . Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008;28:164–71 doi:10.1038/sj.jcbfm.9600504 pmid:17473851

   CrossRefPubMed
9. 9.↵
   2. MacDonald ME,
   3. Frayne R

   . Cerebrovascular MRI: a review of state-of-the-art approaches, methods and techniques. NMR Biomed 2015;28:767–91 doi:10.1002/nbm.3322 pmid:26010775

   CrossRefPubMed
10. 10.↵
    2. Boxerman JL,
    3. Hamberg LM,
    4. Rosen BR, et al

    . MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555–66 doi:10.1002/mrm.1910340412 pmid:8524024

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Weisskoff RM,
    3. Zuo CS,
    4. Boxerman JL, et al

    . Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 1994;31:601–10 doi:10.1002/mrm.1910310605 pmid:8057812

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Ge Y,
    3. Law M,
    4. Johnson G, et al

    . Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol 2005;26:1539–47 pmid:15956527

    Abstract/FREE Full Text
13. 13.↵
    2. Peruzzo D,
    3. Castellaro M,
    4. Calabrese M, et al

    . Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study. J Cereb Blood Flow Metab 2013;33:457–63 doi:10.1038/jcbfm.2012.192 pmid:23250108

    CrossRefPubMed
14. 14.↵
    2. Barth M,
    3. Breuer F,
    4. Koopmans PJ, et al

    . Simultaneous multislice (SMS) imaging techniques. Magn Reson Med 2016;75:63–81 doi:10.1002/mrm.25897 pmid:26308571

    CrossRefPubMed
15. 15.↵
    2. Todd N,
    3. Moeller S,
    4. Auerbach EJ, et al

    . Evaluation of 2D multiband EPI imaging for high-resolution, whole-brain, task-based fMRI studies at 3T: sensitivity and slice leakage artifacts. Neuroimage 2016;124(Pt A):32–42 doi:10.1016/j.neuroimage.2015.08.056 pmid:26341029

    CrossRefPubMed
16. 16.↵
    2. Tofts PS,
    3. Brix G,
    4. Buckley DL, et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32 pmid:10508281

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Gaitán MI,
    3. Shea CD,
    4. Evangelou IE, et al

    . Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70:22–29 doi:10.1002/ana.22472 pmid:21710622

    CrossRefPubMed
18. 18.↵
    2. Williams DS,
    3. Detre JA,
    4. Leigh JS, et al

    . Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci U S A 1992;89:212–16 doi:10.1073/pnas.89.1.212 pmid:1729691

    Abstract/FREE Full Text
19. 19.↵
    2. Alsop DC,
    3. Detre JA,
    4. Golay X, et al

    . Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 2015;73:102–16 doi:10.1002/mrm.25197 pmid:24715426

    CrossRefPubMed
20. 20.↵
    2. Wuerfel J,
    3. Bellmann-Strobl J,
    4. Brunecker P, et al

    . Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004;127(Pt 1):111–19 doi:10.1093/brain/awh007 pmid:14570816

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Lassmann H

    . The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18:563–76, ix doi:10.1016/j.nic.2008.06.005 pmid:19068402

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Ingrisch M,
    3. Sourbron S,
    4. Morhard D, et al

    . Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T. Invest Radiol 2012;47:252–58 doi:10.1097/RLI.0b013e31823bfc97 pmid:22373532

    CrossRefPubMed
23. 23.↵
    2. Haselhorst R,
    3. Kappos L,
    4. Bilecen D, et al

    . Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging 2000;11:495–505 pmid:10813859

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Li L,
    3. Chopp M,
    4. Nejad-Davarani SP, et al

    . Perfusion and diffusion abnormalities of multiple sclerosis lesions and relevance of classified lesions to disease status. J Neurol Neurophysiol 2014;2014(Suppl 12):12 doi:10.4172/2155-9562.S12-012 pmid:25642354

    CrossRefPubMed
25. 25.↵
    2. Adhya S,
    3. Johnson G,
    4. Herbert J, et al

    . Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 2006;33:1029–35 doi:10.1016/j.neuroimage.2006.08.008 pmid:16996280

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Debernard L,
    3. Melzer TR,
    4. Van Stockum S, et al

    . Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiary 2014;85:544–51 doi:10.1136/jnnp-2013-305612 pmid:24039024

    Abstract/FREE Full Text
27. 27.↵
    2. Steen C,
    3. D'haeseleer M,
    4. Hoogduin JM, et al

    . Cerebral white matter blood flow and energy metabolism in multiple sclerosis. Mult Scler 2013;19:1282–89 doi:10.1177/1352458513477228 pmid:23428956

    CrossRefPubMed
28. 28.↵
    2. Narayana PA,
    3. Zhou Y,
    4. Hasan KM, et al

    . Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis. Mult Scler 2014;20:365–73 doi:10.1177/1352458513495936 pmid:23836878

    CrossRefPubMed
29. 29.↵
    2. Rashid W,
    3. Parkes LM,
    4. Ingle GT, et al

    . Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiary 2004;75:1288–93 doi:10.1136/jnnp.2003.026021 pmid:15314117

    Abstract/FREE Full Text
30. 30.↵
    2. Varga AW,
    3. Johnson G,
    4. Babb JS, et al

    . White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci 2009;282:28–33 doi:10.1016/j.jns.2008.12.036 pmid:19181347

    CrossRefPubMed
31. 31.↵
    2. Inglese M,
    3. Park SJ,
    4. Johnson G, et al

    . Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 2007;64:196–202 doi:10.1001/archneur.64.2.196 pmid:17296835

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Doche E,
    3. Lecocq A,
    4. Maarouf A, et al

    . Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. J Neuroradiol 2017;44:158–64 doi:10.1016/j.neurad.2016.10.001 pmid:27865557

    CrossRefPubMed
33. 33.↵
    2. Ota M,
    3. Sato N,
    4. Nakata Y, et al

    . Abnormalities of cerebral blood flow in multiple sclerosis: a pseudocontinuous arterial spin labeling MRI study. Magn Reson Imaging 2013;31:990–95 doi:10.1016/j.mri.2013.03.016 pmid:23582984

    CrossRefPubMed
34. 34.↵
    2. Ingrisch M,
    3. Sourbron S,
    4. Herberich S, et al

    . Dynamic contrast-enhanced magnetic resonance imaging suggests normal perfusion in normal-appearing white matter in multiple sclerosis. Invest Radiol 2017;52:135–41 doi:10.1097/RLI.0000000000000320 pmid:27548346

    CrossRefPubMed
35. 35.↵
    2. Papadaki EZ,
    3. Mastorodemos VC,
    4. Amanakis EZ, et al

    . White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome. Magn Reson Med 2012;68:1932–42 doi:10.1002/mrm.24194 pmid:22367604

    CrossRefPubMed
36. 36.↵
    2. Amann M,
    3. Achtnichts L,
    4. Hirsch JG, et al

    . 3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. Mult Scler 2012;18:1570–76 doi:10.1177/1352458512441984 pmid:22466702

    CrossRefPubMed
37. 37.↵
    2. Bester M,
    3. Forkert ND,
    4. Stellmann JP, et al

    . Increased perfusion in normal appearing white matter in high inflammatory multiple sclerosis patients. PLoS One 2015;10:e0119356 doi:10.1371/journal.pone.0119356 pmid:25774497

    CrossRefPubMed
38. 38.↵
    2. Hyland M,
    3. Rudick RA

    . Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Curr Opin Neurol 2011;24:255–61 doi:10.1097/WCO.0b013e3283460542 pmid:21455068

    CrossRefPubMed
39. 39.↵
    2. Feys P,
    3. Lamers I,
    4. Francis G, et al

    ; Multiple Sclerosis Outcome Assessments Consortium. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 2017;23:711–20 doi:10.1177/1352458517690824 pmid:28206826

    CrossRefPubMed
40. 40.↵
    2. D'haeseleer M,
    3. Steen C,
    4. Hoogduin JM, et al

    . Performance on Paced Auditory Serial Addition Test and cerebral blood flow in multiple sclerosis. Acta Neurol Scand 2013;128:e26–29 doi:10.1111/ane.12129 pmid:23550954

    CrossRefPubMed
41. 41.↵
    2. Francis PL,
    3. Jakubovic R,
    4. O'Connor P, et al

    . Robust perfusion deficits in cognitively impaired patients with secondary-progressive multiple sclerosis. AJNR Am J Neuroradiol 2013;34:62–67 doi:10.3174/ajnr.A3148 pmid:22700746

    Abstract/FREE Full Text
42. 42.↵
    2. Penner IK

    . Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions. Acta Neurol Scand 2016;134(suppl 200):19–23 doi:10.1111/ane.12651 pmid:27580902

    CrossRefPubMed
43. 43.↵
    2. Ramalho J,
    3. Semelka RC,
    4. Ramalho M, et al

    . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2016;37:1192–98 doi:10.3174/ajnr.A4615 pmid:26659341

    Abstract/FREE Full Text
44. 44.↵
    2. Marshall O,
    3. Lu H,
    4. Brisset JC, et al

    . Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol 2014;71:1275–81 doi:10.1001/jamaneurol.2014.1668 pmid:25133874

    CrossRefPubMed
45. 45.↵
    2. Field AS,
    3. Laurienti PJ,
    4. Yen YF, et al

    . Dietary caffeine consumption and withdrawal: confounding variables in quantitative cerebral perfusion studies? Radiology 2003;227:129–35 doi:10.1148/radiol.2271012173 pmid:12616005

    CrossRefPubMedWeb of Science
46. 46.↵
    2. Trangmar SJ,
    3. Chiesa ST,
    4. Llodio I, et al

    . Dehydration accelerates reductions in cerebral blood flow during prolonged exercise in the heat without compromising brain metabolism. Am J Physiol Heart Circ Physiol 2015;309:598–607 doi:10.1152/ajpheart.00525.2015 pmid:26371170

    CrossRefPubMed
47. 47.↵
    2. Mathew RJ,
    3. Wilson WH

    . Substance abuse and cerebral blood flow. Am J Psychiatry 1991;148:292–305 doi:10.1176/ajp.148.3.292 pmid:1992832

    CrossRefPubMedWeb of Science
48. 48.↵
    2. Calamante F

    . Arterial input function in perfusion MRI: a comprehensive review. Prog Nucl Magn Reson Spectrosc 2013;74:1–32 doi:10.1016/j.pnmrs.2013.04.002 pmid:24083460

    CrossRefPubMed
49. 49.↵
    2. De Keyser J,
    3. Steen C,
    4. Mostert JP, et al

    . Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab 2008;28:1645–51 doi:10.1038/jcbfm.2008.72 pmid:18594554

    CrossRefPubMed
50. 50.↵
    2. Hernández-Torres E,
    3. Kassner N,
    4. Forkert ND, et al

    . Anisotropic cerebral vascular architecture causes orientation dependency in cerebral blood flow and volume measured with dynamic susceptibility contrast magnetic resonance imaging. J Cereb Blood Flow Metab 2017;37:1108–19 doi:10.1177/0271678X16653134 pmid:27259344

    CrossRefPubMed
51. 51.↵
    2. Doucette J,
    3. Wei L,
    4. Kames C, et al

    . Anisotropic cerebral vascular architecture causes orientation dependency in cerebral blood flow and volume measured with spin echo dynamic susceptibility contrast magnetic resonance imaging. In: Proceedings of the Annual Meeting of the International Society for Magnetic Resonance in Medicine, Honolulu, Hawaii. April 22–27, 2017
52. 52.↵
    2. Deichmann R,
    3. Gottfried J,
    4. Hutton C, et al

    . Optimized EPI for fMRI studies of the orbitofrontal cortex. Neuroimage 2003;19(2 Pt 1):430–41 doi:10.1016/S1053-8119(03)00073-9 pmid:12814592

    CrossRefPubMedWeb of Science
53. 53.↵
    2. D'haeseleer M,
    3. Cambron M,
    4. Vanopdenbosch L, et al

    . Vascular aspects of multiple sclerosis. Lancet Neurol 2011;10:657–66 doi:10.1016/S1474-4422(11)70105-3 pmid:21683931

    CrossRefPubMedWeb of Science
54. 54.↵
    2. Christiansen CF,
    3. Christensen S,
    4. Farkas DK, et al

    . Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 2010;35:267–74 doi:10.1159/000320245 pmid:20881430

    CrossRefPubMedWeb of Science
55. 55.↵
    2. Aboul-Enein F,
    3. Rauschka H,
    4. Kornek B, et al

    . Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003;62:25–33 doi:10.1093/jnen/62.1.25 pmid:12528815

    CrossRefPubMed
56. 56.↵
    2. D'haeseleer M,
    3. Beelen R,
    4. Fierens Y, et al

    . Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci U S A 2013;110:5654–58 doi:10.1073/pnas.1222560110 pmid:23509249

    Abstract/FREE Full Text
57. 57.↵
    2. Saindane AM,
    3. Law M,
    4. Ge Y, et al

    . Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol 2007;28:767–72 pmid:17416836

    Abstract/FREE Full Text
58. 58.↵
    2. Holland CM,
    3. Charil A,
    4. Csapo I, et al

    . The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging 2012;22:129–36 doi:10.1111/j.1552-6569.2011.00585.x pmid:21447022

    CrossRefPubMedWeb of Science
59. 59.↵
    2. Haider L,
    3. Zrzavy T,
    4. Hametner S, et al

    . The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016;139(Pt 3):807–15 doi:10.1093/brain/awv398 pmid:26912645

    CrossRefPubMed
60. 60.↵
    2. Mahad DH,
    3. Trapp BD,
    4. Lassmann H

    . Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015;14:183–93 doi:10.1016/S1474-4422(14)70256-X pmid:25772897

    CrossRefPubMed
61. 61.↵
    2. Wise RG,
    3. Harris AD,
    4. Stone AJ, et al

    . Measurement of OEF and absolute CMRO2: MRI-based methods using interleaved and combined hypercapnia and hyperoxia. Neuroimage 2013;83:135–47 doi:10.1016/j.neuroimage.2013.06.008 pmid:23769703

    CrossRefPubMed